02315.HK
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 60.60
−5.53%Margins
Gross margin
78.0%
EBITDA margin
33.6%
EBIT margin
24.3%
Net margin
17.2%
FCF margin
16.6%
20.5%
Return on equity
13.6%
Return on assets
21.2%
Return on invested capital
0.78x
Asset turnover
HKD 927.9M
Cash from operations
HKD 3.03
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026